INT180883

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2005
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 4.63
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (MT1E) cytoplasm (MT1E)
Anatomy Link Frequency
fibroblasts 1
MT1E (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 3 86.48 High High
Pain 6 70.88 Quite High
addiction 1 16.08 Low Low
headache 4 5.88 Low Low
Multiple sclerosis 20 5.00 Very Low Very Low Very Low
cytokine 9 5.00 Very Low Very Low Very Low
abdominal pain 4 5.00 Very Low Very Low Very Low
metalloproteinase 4 5.00 Very Low Very Low Very Low
cva 3 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adhesions 133 99.72 Very High Very High Very High
Toxicity 102 98.20 Very High Very High Very High
Death 6 97.52 Very High Very High Very High
Body Weight 24 94.32 High High
Diarrhoea 24 93.92 High High
Cancer 120 93.64 High High
Exanthema 24 93.12 High High
Lymphopenia 12 91.28 High High
Solid Tumor 29 90.32 High High
Disease 47 80.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Therefore, it is likely that these molecules may increase adhesion formation by augmenting MT-IE levels which in turn may increase proliferation, reduce cell death and confer invasiveness of adhesion fibroblasts [36].
Positive_regulation (augmenting) of MT-IE in fibroblasts associated with death and adhesions
1) Confidence 0.27 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC548295 Disease Relevance 0.99 Pain Relevance 0
In conclusion, the MTD of pertuzumab was not reached up to a dose of 25 mg/kg and acceptable tolerability was confirmed.
Neg (not) Positive_regulation (reached) of MTD
2) Confidence 0.08 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.58 Pain Relevance 0
MTD was not reached up to a dose level of 25 mg/kg.
Neg (not) Positive_regulation (reached) of MTD
3) Confidence 0.08 Published 2009 Journal Japanese Journal of Clinical Oncology Section Abstract Doc Link PMC2661001 Disease Relevance 0.95 Pain Relevance 0
Although one DLT was observed at the 25 mg/kg dose level, pertuzumab was generally well tolerated and the MTD of pertuzumab was not reached up to a dose level of 25 mg/kg.
Neg (not) Positive_regulation (reached) of MTD associated with toxicity
4) Confidence 0.08 Published 2009 Journal Japanese Journal of Clinical Oncology Section Body Doc Link PMC2661001 Disease Relevance 0.77 Pain Relevance 0
The MTD was reached at PLD doses of 30 and 40 mg/m2, every 21 or 28 days, and at TPT doses (0.5 to 1.0 mg/m2/day) administered with the classic shorter courses (days 1 to 3 or days 1 to 5).
Positive_regulation (reached) of MTD
5) Confidence 0.03 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2952486 Disease Relevance 0.50 Pain Relevance 0
This resulted in three additional genes (IFI44L, MT1E and IMAGE:1879725; R<?
Positive_regulation (resulted) of MT1E
6) Confidence 0.03 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2271130 Disease Relevance 0 Pain Relevance 0
g upon reaching the MTD.
Positive_regulation (reaching) of MTD
7) Confidence 0.02 Published 2008 Journal Drug design, development and therapy Section Body Doc Link PMC2761172 Disease Relevance 0.84 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox